Real-time Estimate
Cboe BZX
10:25:34 2024-05-17 EDT
|
5-day change
|
1st Jan Change
|
0.721
USD
|
+0.14%
|
|
-9.96%
|
-38.76%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
292.4
|
214.2
|
21.61
|
25.23
|
21.26
|
-
|
-
|
Enterprise Value (EV)
1 |
292.4
|
214.2
|
-30.85
|
25.23
|
21.26
|
21.26
|
21.26
|
P/E ratio
|
-
|
-
|
-0.33
x
|
-0.62
x
|
-0.57
x
|
-0.74
x
|
-0.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
24.4
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
24.4
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-128
x
|
-6.36
x
|
-0.36
x
|
-
|
-0.79
x
|
-0.52
x
|
-0.37
x
|
FCF Yield
|
-0.78%
|
-15.7%
|
-276%
|
-
|
-127%
|
-193%
|
-273%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
13,984
|
21,021
|
21,190
|
21,381
|
29,534
|
-
|
-
|
Reference price
2 |
20.91
|
10.19
|
1.020
|
1.180
|
0.7200
|
0.7200
|
0.7200
|
Announcement Date
|
21-03-22
|
22-03-29
|
23-03-28
|
24-03-29
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.87
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-0.0448
|
-10.71
|
-62.66
|
-71.1
|
-42.61
|
-28.73
|
-35.4
|
-56
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-6,436.78%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-65.37
|
-40.16
|
-28.92
|
-34.8
|
-54
|
Net income
1 |
-
|
-
|
-
|
-65.37
|
-40.16
|
-28.92
|
-34.8
|
-54
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-6,206.9%
|
EPS
2 |
-0.0100
|
-
|
-
|
-3.110
|
-1.890
|
-1.260
|
-0.9733
|
-1.030
|
Free Cash Flow
1 |
-
|
-2.28
|
-33.66
|
-59.6
|
-
|
-27
|
-41
|
-58
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-6,666.67%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-10-08
|
21-03-22
|
22-03-29
|
23-03-28
|
24-03-29
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-17.71
|
-21.63
|
-19.62
|
-15.59
|
-15.42
|
-15.1
|
-11.66
|
-10.32
|
-5.533
|
-7.478
|
-6.863
|
-6.746
|
-6.99
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-16.88
|
-13.64
|
-14.34
|
-11.15
|
-9.715
|
-4.95
|
-12.43
|
-6.413
|
-6.311
|
-6.51
|
Net income
1 |
-
|
-
|
-
|
-16.88
|
-13.64
|
-14.34
|
-11.15
|
-9.715
|
-4.95
|
-12.43
|
-6.413
|
-6.311
|
-6.51
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-
|
-
|
-
|
-0.8000
|
-0.6500
|
-0.6800
|
-0.5200
|
-0.4600
|
-0.2300
|
-0.5800
|
-0.2400
|
-0.2400
|
-0.2400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22-03-29
|
22-05-12
|
22-08-11
|
22-11-10
|
23-03-28
|
23-05-11
|
23-08-07
|
23-11-14
|
24-03-29
|
24-05-14
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
52.5
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-2.28
|
-33.7
|
-59.6
|
-
|
-27
|
-41
|
-58
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.26
|
-
|
-
|
-
|
1
|
1
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
114.94%
|
Announcement Date
|
21-03-22
|
22-03-29
|
23-03-28
|
24-03-29
|
-
|
-
|
-
|
Last Close Price
0.72
USD Average target price
9
USD Spread / Average Target +1,150.00% Consensus |
1st Jan change
|
Capi.
|
---|
| -38.76% | 21.26M | | +8.60% | 114B | | +10.65% | 104B | | -12.74% | 22.41B | | -0.67% | 22.28B | | -5.80% | 19.07B | | -37.36% | 18B | | -5.13% | 17.89B | | +7.46% | 14.28B | | +36.38% | 12.55B |
Bio Therapeutic Drugs
|